Plasmalogen precursors for Alzheimer’s are named as first program candidate There are nutrients and dietary compounds ...

In this forward-looking whitepaper, Blue Mountain explores how agentic AI —autonomous, context-aware AI agents—could ...

Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to ...

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...

Psychedelic drug development can still benefit from the FDA Commissioner’s National Priority Review Voucher Pilot Program, though the CNPV designation was not given to Compass Pathways’ synthetic ...

The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...

The Food and Drug Administration (FDA) development and approval process for drugs and medical devices involves multiple phases that ensure the safety and effectiveness of products before and after ...

The FDA has proposed new guidelines to expedite the approval of customized treatments for rare diseases, creating a streamlined pathway for bespoke therapies that could address unmet medical needs.

Six weeks after a reduction in force (RIF) at the US Food and Drug Administration removed thousands of workers, signs are emerging about how the agency’s approach to drug approval may change. The 20% ...

Makary urged the Trump administration to partner with the pharmaceutical industry. ・The senior official is of the opinion ...